The multiple myeloma therapy market has witnessed considerable advances in recent years. Effective therapies such as Thalomid, Revlimid, Velcade, Pomalyst, and Kyprolis have transformed the treatment of this disease, and the treatment algorithms for multiple myeloma continue to evolve, driven by the 2015 approval of several novel, high-priced therapies with new mechanisms of action. This analysis provides insight on current and anticipated use of approved therapies for multiple myeloma and on hematologist-oncologists’ perception of these therapies.


Related Reports

Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast

The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed...

View Details

Multiple Myeloma - Epidemiology - Emerging Markets

DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries w...

View Details

Multiple Myeloma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We re...

View Details

Multiple Myeloma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient pop...

View Details